title: [The use of nifedipine in gastric and duodenal peptic ulcer].
abstract: It has been ascertained that use of nifedipine in antiulcer therapy is justified from the clinical standpoint as well as pathogenetically substantiated since its incorporation into the complex of therapeutic measures designed to treat patients with ulcer disease makes for a speedier cicatrization of ulcers as well as augmentation of the gastric mucose levels of periodic acid-Schiff reaction-positive substances and acid mucopolysaccharides, dispelling of hyperthermia foci, increase in bioelectric potentials and activation of motion of nuclei of epithelial cells of the pyloric portion of the stomach.
authors.forename: A G
authors.initials: AG
authors.lastname: Oparin
authors.forename: I P
authors.initials: IP
authors.lastname: Korenovskiĭ
authors.forename: V Iu
authors.initials: VIu
authors.lastname: Chonka
authors.forename: Iu G
authors.initials: IuG
authors.lastname: Fedchenko
authors.forename: T I
authors.initials: TI
authors.lastname: Demerchan
authors.forename: E L
authors.initials: EL
authors.lastname: Iakovenko
mesh_terms: D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D002908:Chronic Disease; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D004381:Duodenal Ulcer / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D012074:Remission Induction; D013276:Stomach Ulcer / Q000188:drug therapy*
chemical_list: D000897:Anti-Ulcer Agents; D002121:Calcium Channel Blockers; D009543:Nifedipine